We use cookies for a better user experience. Read our Privacy Policy

I Agree

Plasma Protein Therapeutics Market

Plasma Protein Therapeutics Market (Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase inhibitors, Others), Applications (Hemophilia, Primary Immunodeficiency, Disorder (PID), Idiopathic Thrombocytopenic, Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Indications) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • According to Transparency Market Research’s latest report on the Plasma Protein Therapeutics Market for the historical period 2017–2018 and forecast period 2019–2027, Growing Investment in Innovation, Rising Demand for Immunoglobulin (IG), Rising Indications and Therapeutic use of Plasma Derived Protein Therapeutics are projected to drive the plasma protein therapeutics market
  • According to the report, the Plasma Protein Therapeutics Market was valued at US$ 22.41 Bn in 2018 and is projected to expand at a CAGR of 7.0% from 2019 to 2027

To know the scope of our report Get a Sample on Plasma Protein Therapeutics Market

Growing Investment in Innovation: Key Drivers

  • Quality and advancements have been the success drivers of the plasma protein industry in order to increase the quality of life of patients and to guarantee donor safety. Plasma acquired via apheresis technology or complete blood donation processing can either be assembled or fractionated into plasma protein products that comprise one or more purified plasma protein or transfused directly to patients.
  • The plasma protein industry has been investing in research and development of new plasma proteins therapies (e.g.: Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients. In March 2016, Grifols announced that it will invest US$ 360 Mn to expand production capabilities for plasma-derived therapies. The investment will increase the plasma fractionation capacity and purification of several proteins.
  • This has been also evident from advancements such as the product presentations (e.g. subcutaneous IG, IVIG 10% concentration, and IVIG liquid presentation), manufacturing process (e.g. improvement of yield), added virus elimination technologies (e.g. nanofiltration), and development of new plasma proteins (e.g. protein C and purified factor V)
  • Technological advancements in efficient and cost-effective procedures for fractionating proteins from plasma are anticipated to boost the plasma protein therapeutic market. According to the World Health Organization, global blood donation come from the high income countries, i.e., more than half of the 108 million, which is the home for 18% of the world’s population.
  • Rising incidence of over 200 life threatening diseases affecting immune or neurological system such as chronic inflammatory demyelinating polyneuropathy (CIPD), multifocal motor neuropathy (MMN), ideopathic thrombocytopenic purpura (ITP), and other infectious diseases including hepatitis A&B, rabies, tetanus, and varicella is driving the market.

Get a glimpse of the in-depth analysis through our Report Brochure

Rising Demand for Immunoglobulins (IG)

  • The number of clinical indications for IG has been increasing. IG has become an important treatment option in a number of clinical indications beyond primary immunodeficiency, including autoimmune and acute inflammatory conditions. Also, off-label prescribing has crossed over into almost every medical specialty. Chronic use of off-label prescribing in some indications, particularly for the treatment of some neurological illnesses, in addition to immune deficiencies is increasing demand for IG.
  • Plasma-derived IG is used for a wide range of autoimmune and inflammatory diseases. Increased recognition and treatment of immune deficiencies in developing world have added to the global demand for IG. However, increased use of high dose therapy, particularly in autoimmune neurologic diseases is the major reason for the continued strong growth in demand for IG products.
  • Widespread off-label use of IG demonstrates use of large volume of plasma. Examples of most common off-label uses for IVIG in the U.S. are multifocal motor neuropathy (MMN), acute panautonomic polyneuropathy, hemolytic disease of the newborn, autoimmune mucocutaneous blistering diseases, and acute cardiomyopathy.
  • The clinical demand for these medicines has increased in the past few years and the trend is likely to continue due to constant improvement in diagnosis and improved life-expectancy

Stringent Regulation and Reimbursement Issues Threat to Hamper Market

  • The plasma collection standards in emerging countries do not match those required by the fractionators. These regions follow strict rules and regulations regarding the quality of their operations, starting with the quality of the raw material. Specific fractionators are designed for plasma. For instance, the European health authorities require that the plasma pool for fractionation be tested for HIV, hepatitis A, B and C, and Parvovirus B. The blood collected by many centers is often unable to comply with these regulations, causing some recovered plasma to be unused.
  • Health budgets have been subjected to growing pressures. Funding through reimbursement pathways from private and public payers has come under inspection and it has drawn plasma protein therapies into the landscape of Health Technology Assessments (HTA), including the possible application of cost-utility analysis (CUA) in the distribution of reimbursement funds. Given the high cost of the therapies and the comparatively nascent nature of many of the indications, application of these tools of health economics can constraint the supply of products for patients in genuine need.
  • Regulatory and quality policies affect every step of the plasma protein therapy lifecycle, which includes donor safety, quality and compliance, biological license application process, therapy safety and efficacy, and pharmacovigilance. For example, licensing and inspecting of plasma collection centers and plasma protein therapy manufacturing facilities can be tedious and time consuming.
  • Plasma protein therapies used by Medicare beneficiaries predominately are reimbursed through Medicare Part B, which covers physician-administered therapies. In addition to being a complex technology, prices of raw materials and multiple safety measures contribute to the cost of these products. Hence, it is essential that reimbursement for plasma protein therapies is sufficient to maintain access.

Expanding operations in future? To get the perfect launch ask for a custom report 

Plasma Protein Therapeutics Market: Competitive Landscape

  • This report profiles major players in the plasma protein therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The plasma protein therapeutics market is fragmented, with the presence of a number of international as well as regional players
  • Various players operating in the plasma protein therapeutics market are
    • Baxter International
    • Biotests
    • CSL Behring
    • GRIFOLS, S.A
    •  Kedrion
    • Octapharma USA, Inc.
    • Shire Plc.
    • China Biologics.

Plasma Protein Therapeutics Market: Key Developments

Key players in the plasma protein therapeutics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies of key players are likely to fuel the growth of the plasma protein therapeutics market. A few expansion strategies adopted by players operating in the plasma protein therapeutics market are:

  • In September 2015, Shire Plc. launched Vynase, the only drug that was approved by US FDA for treatment of Adult Binge eating disorder.
  • In October 2015, Shire Plc. merged with Baxalta, Inc., for 32$bn which is completed in June, 2016 and this move makes Shire Plc. One of the leading manufacturers of products for various rare diseases associated with immune disorders.
  • In February, 2015, Shire completed acquisition of NPS Pharma
  • In January, 2016 Shire also completed the acquisition of Dyax corp which is primarily focused on the development of plasma kallikrein (pKal) inhibitors for the treatment of HAE, a debilitating and sometimes life-threatening rare genetic disease
  • In April 2016, Octapharma invested US$90 Mn and became a minority shareholder of Glycotope GmbH Berlin. It also acquired the worldwide license to certain IP of Glycotope’s recombinant technology. A series of research and development projects of Glycotope is commissioned by Octapharma to enable the technology transfer and accelerated development of certain therapeutic proteins.
  • In January, 2016, Octapharma announced the U.S. availability of NUWIQ for the treatment of children and adult with Hemophilia A. Octapharma is further investing in NUWIQ for the benefit of patients with clinical studies of the dosing process to improve protection against bleeding episodes and reduce the frequency of dosing with personalized prophylaxis.
  • In August 2013, Octapharma USA announced the accessibility of Octaplas, a solvent/detergent (S/D) treated, pooled human plasma designated for the replacement of multiple coagulation factors in patients with acquired deficiencies due to undergoing cardiac surgery or liver transplant or liver disease.

The report on the plasma protein therapeutics market discussed individual strategies, followed by company profiles of manufacturers of plasma protein therapeutics market. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the plasma protein therapeutics market.

Global Plasma Protein Therapeutics Market- Segmentation

Product

Immunoglobulin

Albumin

Coagulation Factor

C1-esterase inhibitors

Others

Application

Primary Immunodeficiency Disorder (PID)

Idiopathic Thrombocytopenic Purpura

Secondary Immunodeficiency

Hereditary Angioedema

Other Indications

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Plasma Protein Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of plasma protein therapeutics market?

Plasma protein therapeutics market is estimated to reach a valuation of US$ 35,350.1 Mn by 2027

What is the anticipated CAGR of the plasma protein therapeutics market in the forecast period?

Plasma protein therapeutics market is projected to expand at a CAGR of 7.0% from 2019 to 2027

What are the key driving factors for the growth of the plasma protein therapeutics market?

Plasma protein therapeutics market is driven by rising indications and therapeutic use of plasma derived protein therapeutics

Which is the rising prominent segment in the plasma protein therapeutics market?

The immunoglobulin segment dominated the global plasma protein therapeutics market during the forecast period

Who are the key players in the plasma protein therapeutics market?

Key players in the plasma protein therapeutics market include Octapharma USA, Inc., CSL Behring, China Biologics, GRIFOLS, S.A, and Biotests

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Plasma Protein Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Phase 1 and Phase 2 Drugs (Qualitative Analyses)

    5.3. Phase 3 Drugs (Quantitative)

6. Global Plasma Protein Therapeutics Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        6.2.1. Immunoglobulin 

        6.2.2. Albumin 

        6.2.3. Coagulation Factor

        6.2.4. C1-esterase inhibitors

        6.2.5. Others

    6.3. Global Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        6.3.1. Hemophilia

        6.3.2. Primary Immunodeficiency Disorder (PID)

        6.3.3. Idiopathic Thrombocytopenic Purpura

        6.3.4. Secondary Immunodeficiency

        6.3.5. Hereditary Angioedema

        6.3.6. Other Indications

    6.4. Global Plasma Protein Therapeutics Market Attractiveness, by Product

    6.5. Global Plasma Protein Therapeutics Market Attractiveness, by Application

7. Global Plasma Protein Therapeutics Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Global Plasma Protein Therapeutics Market Value Forecast, by Region

        7.2.1. North America 

        7.2.2. Europe 

        7.2.3. Asia Pacific 

        7.2.4. Latin America 

        7.2.5. Middle East & Africa 

    7.3. Global Plasma Protein Therapeutics Market Attractiveness, by Region

8. North America Plasma Protein Therapeutics Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. North America Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        8.2.1. Immunoglobulin 

        8.2.2. Albumin 

        8.2.3. Coagulation Factor

        8.2.4. C1-esterase inhibitors

        8.2.5. Others

    8.3. North America Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        8.3.1. Hemophilia

        8.3.2. Primary Immunodeficiency Disorder (PID)

        8.3.3. Idiopathic Thrombocytopenic Purpura

        8.3.4. Secondary Immunodeficiency

        8.3.5. Hereditary Angioedema

        8.3.6. Other Indications

    8.4. North America Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027

        8.4.1. U.S.

        8.4.2. Canada

    8.5. North America Plasma Protein Therapeutics Market Attractiveness Analysis 

        8.5.1. By Product 

        8.5.2. By Application 

        8.5.3. By Country

9. Europe Plasma Protein Therapeutics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

10. Europe Plasma Protein Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        10.2.1. Immunoglobulin 

        10.2.2. Albumin 

        10.2.3. Coagulation Factor

        10.2.4. C1-esterase inhibitors

        10.2.5. Others

    10.3. Europe Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        10.3.1. Hemophilia

        10.3.2. Primary Immunodeficiency Disorder (PID)

        10.3.3. Idiopathic Thrombocytopenic Purpura

        10.3.4. Secondary Immunodeficiency

        10.3.5. Hereditary Angioedema

        10.3.6. Other Indications

    10.4. Europe Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe 

    10.5. Europe Plasma Protein Therapeutics Market Attractiveness Analysis 

        10.5.1. By Product

        10.5.2. By Application 

        10.5.3. By Country/Sub-region

11. Asia Pacific Plasma Protein Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        11.2.1. Immunoglobulin 

        11.2.2. Albumin 

        11.2.3. Coagulation Factor

        11.2.4. C1-esterase inhibitors

        11.2.5. Others

    11.3. Asia Pacific Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        11.3.1. Hemophilia

        11.3.2. Primary Immunodeficiency Disorder (PID)

        11.3.3. Idiopathic Thrombocytopenic Purpura

        11.3.4. Secondary Immunodeficiency

        11.3.5. Hereditary Angioedema

        11.3.6. Other Indications

    11.4. Asia Pacific Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific 

    11.5. Asia Pacific Plasma Protein Therapeutics Market Attractiveness Analysis 

        11.5.1. By Product

        11.5.2. By Application 

        11.5.3. By Country/Sub-region

12. Latin America Plasma Protein Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        12.2.1. Immunoglobulin 

        12.2.2. Albumin 

        12.2.3. Coagulation Factor

        12.2.4. C1-esterase inhibitors

        12.2.5. Others

    12.3. Latin America Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        12.3.1. Hemophilia

        12.3.2. Primary Immunodeficiency Disorder (PID)

        12.3.3. Idiopathic Thrombocytopenic Purpura

        12.3.4. Secondary Immunodeficiency

        12.3.5. Hereditary Angioedema

        12.3.6. Other Indications

    12.4. Latin America Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America Latin America 

    12.5. Latin America Plasma Protein Therapeutics Market Attractiveness Analysis 

        12.5.1. By Product

        12.5.2. By Application 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Plasma Protein Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        13.2.1. Immunoglobulin 

        13.2.2. Albumin 

        13.2.3. Coagulation Factor

        13.2.4. C1-esterase inhibitors

        13.2.5. Others

    13.3. Middle East & Africa Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        13.3.1. Hemophilia

        13.3.2. Primary Immunodeficiency Disorder (PID)

        13.3.3. Idiopathic Thrombocytopenic Purpura

        13.3.4. Secondary Immunodeficiency

        13.3.5. Hereditary Angioedema

        13.3.6. Other Indications

    13.4. Middle East & Africa Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa 

    13.5. Middle East & Africa Plasma Protein Therapeutics Market Attractiveness Analysis 

        13.5.1. By Product

        13.5.2. By Application 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Mergers & Acquisitions (M&A)

    14.2. Funding

    14.3. Company Profiles

        14.3.1. Dexcom, Inc. 

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Growth Strategies

            14.3.1.3. SWOT Analysis

        14.3.2. Apple, Inc. 

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Growth Strategies

            14.3.2.3. SWOT Analysis

        14.3.3. FitBit, Inc. 

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Growth Strategies

            14.3.3.3. SWOT Analysis

        14.3.4. Withings 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Growth Strategies

            14.3.4.3. SWOT Analysis

        14.3.5. Proteus Digital Health

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Growth Strategies

            14.3.5.3. SWOT Analysis

        14.3.6. Omada Health, Inc. 

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Growth Strategies

            14.3.6.3. SWOT Analysis 

        14.3.7. WellDoc, Inc. 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Growth Strategies

            14.3.7.3. SWOT Analysis

        14.3.8. Livongo Health 

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Growth Strategies

            14.3.8.3. SWOT Analysis

        14.3.9. Noom, Inc. 

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Growth Strategies

            14.3.9.3. SWOT Analysis

        14.3.10. Ginger.io, Inc. 

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Growth Strategies

            14.3.10.3. SWOT Analysis

        14.3.11. Propeller Health 

            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.11.2. Growth Strategies

            14.3.11.3. SWOT Analysis

        14.3.12. 2Morrow, Inc.

            14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.12.2. Growth Strategies

            14.3.12.3. SWOT Analysis

        14.3.13. Canary Health 

            14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.13.2. Growth Strategies

            14.3.13.3. SWOT Analysis

        14.3.14. Mango Health

            14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.14.2. Growth Strategies

            14.3.14.3. SWOT Analysis

        14.3.15. BiogeniQ Inc.

            14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.15.2. Growth Strategies

            14.3.15.3. SWOT Analysis

        14.3.16. Twine Health, Inc.

            14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.16.2. Growth Strategies

            14.3.16.3. SWOT Analysis

        14.3.17. Glooko, Inc.

            14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.17.2. Growth Strategies

            14.3.17.3. SWOT Analysis

        14.3.18. Firstbeat Technologies Ltd 

            14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.18.2. Growth Strategies

            14.3.18.3. SWOT Analysis

        14.3.19. Claritas MindSciences

            14.3.19.1.  Company Overview (HQ, Business Segments, Employee Strength)

            14.3.19.2. Growth Strategies

            14.3.19.3. SWOT Analysis

        14.3.20. Big Health 

            14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.20.2. Growth Strategies

            14.3.20.3. SWOT Analysis

        14.3.21. Dthera Sciences 

            14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.21.2. Growth Strategies

            14.3.21.3. SWOT Analysis

        14.3.22. Virta Health Corp

            14.3.22.1.  Company Overview (HQ, Business Segments, Employee Strength)

            14.3.22.2. Growth Strategies

            14.3.22.3. SWOT Analysis

        14.3.23. Zest Health, LLC 

            14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.23.2. Growth Strategies

            14.3.23.3. SWOT Analysis

        14.3.24. Meru Health, Inc.

            14.3.24.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.24.2. Growth Strategies

            14.3.24.3. SWOT Analysis

        14.3.25. HealthMine, Inc. 

            14.3.25.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.25.2. Growth Strategies

            14.3.25.3. SWOT Analysis

        14.3.26. Pear Therapeutics, Inc. 

            14.3.26.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.26.2. Growth Strategies

            14.3.26.3. SWOT Analysis

        14.3.27. BioTelemetry, Inc. 

            14.3.27.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.27.2. Growth Strategies

            14.3.27.3. SWOT Analysis

        14.3.28. Blue Mesa Health 

            14.3.28.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.28.2. Growth Strategies

            14.3.28.3. SWOT Analysis

        14.3.29. Digital Therapeutics 

            14.3.29.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.29.2. Growth Strategies

            14.3.29.3. SWOT Analysis

List of Tables

Table 1. Plasma Protein Therapeutics Market Snapshot

Table 2. Global Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 3. Global Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 4. Global Plasma Protein Therapeutics Market Revenue, by Region, (US$ Mn), 2017–2027

Table 5. Pipeline Analysis (Phase I and Phase II)

Table 6. Pipeline Analysis (Phase III): Plasma protein Therapeutics, Expected Launch date of Approval to 2027 (US$ Mn)

Table 7. North America Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 8. North America Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 9. Europe Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 10. Europe Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 11. Europe Plasma Protein Therapeutics Market Estimates and Forecast, by Countries, (US$ Mn), 2017–2027

Table 12. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 13. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 14. Asia Pacific Plasma Protein Therapeutics Market Estimates and Forecast, by Countries, (US$ Mn), 2017–2027

Table 15. LATAM Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 16. LATAM Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 17. Latin America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2017–2027

Table 18. ROW Plasma Protein Therapeutics Market Estimates and Forecast, by Product Type, (US$ Mn), 2017–2027

Table 19. ROW Plasma Protein Therapeutics Market Estimates and Forecast, by Application, (US$ Mn), 2017–2027

List of Figures

Figure 1. Global Plasma Protein Therapeutics Market Revenue, (US$ Mn), 2017–2027

Figure 2. Global Plasma Protein Therapeutics Market Revenue, by Product Type (US$ Mn), 2017–2027

Figure 3. Global Plasma Protein Therapeutics Market Revenue, by Application (US$ Mn), 2017–2027

Figure 4. Global Plasma Protein Therapeutics Market, by Geography (%), 2015

Figure 5. Global Plasma Protein Therapeutics Market, by Geography (%), 2024

Figure 6. Market Attractiveness Analysis, by Geography (2015)

Figure 7. Global Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 8. Global Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 9. Global Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 10. Global C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 11. Other Plasma-derived Proteins Market Revenue, (US$ Mn), 2017–2027

Figure 12. Global Hemophilia Market Revenue, (US$ Mn), 2017–2027

Figure 13. Global Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 14. Global Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 15. Global Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 16. Global Hereditary Angioedema Market Revenue, (US$ Mn), 2017–2027

Figure 17. Other Application Market Revenue, (US$ Mn), 2017–2027

Figure 18. Market Positioning of Key

Figure 19. North America Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 20. North America Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 21. North America Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 22. North America C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 23. North America Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 24. North America Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 25. North America Secondary Immunodeficiency Market Estimates and Forecast, (US$ Mn), 2017–2027

Figure 26. North America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2017–2027

Figure 27. Europe Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 28. Europe Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 29. Europe Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 30. Europe C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 31. Europe Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 32. Europe Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 33. Europe Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 34. Asia Pacific Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 35. Asia Pacific Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 36. Asia Pacific Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 37. Asia Pacific C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 38. Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 39. Asia Pacific Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 40. Asia Pacific Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 41. LATAM Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 42. LATAM Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 43. LATAM Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 44. LATAM C1 Esterase inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 45. LATAM Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 46. LATAM Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 47. LATAM Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 48. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 49. Geographical Financial Overview: 2017-2019(US$ Mn)

Figure 50. Financial Overview: 2017-2019(US$ Mn)

Figure 51. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 52. Geographical Overview: 2017-2019(US$ Mn)

Figure 53. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 54. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 55. Geographical Overview: 2017-2019(US$ Mn)

Figure 56. Financial Overview: 2012–2014 (US$ Mn)

Figure 57. Financial Overview: 2017-2019(US$ Mn)

Figure 58. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 59. Geographical Overview: 2017-2019(US$ Mn)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

941

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved